Elucid Names Scott Huennekens Executive Chairman of the Board
Retrieved on:
Tuesday, April 25, 2023
Health, Medical Devices, Technology, Hospitals, Radiology, Artificial Intelligence, Cardiology, IPO, University, Harvard University, Stroke, Marie Cassidy, Cardiovascular disease, MBA, Sale, J&J, Death, Ischemia, Patient, Physician, Risk, Vascular disease, Growth, Johnson & Johnson, FDA, Management, Medical imaging, Elucid, Wolfgang Hünnekens
Elucid, Inc ., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of directors.
Key Points:
- Elucid, Inc ., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of directors.
- He has a proven track record in building innovative companies addressing large, unmet clinical needs,” said Elucid CEO Blake Richards.
- “It is an honor to join Elucid as chairman of the board of directors,” said Huennekens.
- Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.